Study Shows the Need for Psychiatric Care to be Integrated into Cancer Treatment

By |2019-03-28T14:15:40-07:00March 28th, 2019|Brief Bulletins from the Field, We Know Psychiatry|

Patients with prostate, bladder or kidney cancers are at greater risk of dying if they have had psychiatric care prior to the cancer treatment. In addition, patients with these cancers show greater suicide risk than the general population, even once the data is corrected for previous psychiatric care. These are [...]

Biogen, Eisai discontinue Alzheimer’s trials

By |2019-03-21T18:28:53-07:00March 21st, 2019|Brief Bulletins from the Field, We Know Psychiatry|

Biogen and Eisai have announced that they are discontinuing the ENGAGE and EMERGE trials, which were designed to test the efficacy and safety of aducanumab in patients with mild cognitive impairment caused by Alzheimer’s disease and mild Alzheimer’s disease dementia. The phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group trials were [...]

FDA Approves Brexanolone, First Drug for Postpartum Depression

By |2019-03-20T11:48:10-07:00March 20th, 2019|Brief Bulletins from the Field, We Know Psychiatry|

The US Food and Drug Administration (FDA) has approved brexanolone intravenous infusion (Zulresso, Sage Therapeutics), the first-ever drug indicated for the treatment of postpartum depression. The drug is administered under medical supervision as a continuous infusion over a total of 60 hours (2.5 days), according to the FDA. Postpartum depression can [...]

Alzheimer Drug Plus SSRI May Improve Depression/Cognition

By |2019-03-06T13:40:42-07:00March 6th, 2019|Brief Bulletins from the Field, Uncategorized, We Know Psychiatry|

Adding the Alzheimer drug memantine (Namenda, Allergan) to treatment with a selective serotonin reuptake inhibitor may improve depressive symptoms, executive function, and other outcomes in older patients with both depression and cognitive complaints, new research suggests. The findings were presented at the American Association of Geriatric Psychiatry (AAGP) 2019. In a [...]

FDA Approves Intranasal Ketamine for Major Depressive Disorder

By |2019-03-06T08:05:04-07:00March 6th, 2019|Brief Bulletins from the Field, We Know Psychiatry|

The Food and Drug Administration yesterday approved an intranasal form of esketamine for treatment-resistant depression in adults who have failed at least two oral antidepressants of different classes. The spray, from Janssen Pharmaceutical (Spravato) is available in tamper-resistant prepackaged units of one, two, or three devices to deliver the prescribed doses [...]

Combination of Ketamine and Naltrexone Shows Promise for Addiction Treatments and Depression

By |2019-01-18T11:06:43-07:00January 18th, 2019|Brief Bulletins from the Field, We Know Psychiatry|

  A preliminary study of five patients suffering from both depression and substance abuse disorders suggest that isn’t the case. The study was published Jan. 9 in the journal JAMA Psychiatry. Substance abuse and depression are common in many patients, and efforts to treat both conditions simultaneously have had limited [...]

Study Links Increased Risk of Mental Disorders with Childhood Infections

By |2018-12-06T11:40:55-07:00December 6th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

Furthering the role of immune system disorders in the development of mental disorders, recent research links infections that children contract during their childhood with increased risk of mental disorders during childhood and adolescence. The first study of its kind shows that high temperatures, sore throats and infections during childhood can [...]

Cassipa Approved by FDA for Opioid Dependence

By |2018-09-12T15:28:07-07:00September 12th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

A new dosage strength of buprenorphine and naloxone sublingual film was approved recently by the Food and Drug Administration. Cassipa sublingual film, made by Teva Pharmaceuticals, is a 16 mg/4 mg dosage of buprenorphine and naloxone for the maintenance treatment of opioid dependence. Buprenorphine and naloxone sublingual film also is [...]

Seven-Year Analysis on Benzodiazepine Prescribing for Children, Adolescents, and Young Adults Showed Marked Increase

By |2018-08-09T08:01:59-07:00August 9th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

Conclusions The overall increase in prevalence rates of BZD dispensations during the study period and the unexpectedly high proportion of individuals who were prescribed a BZD on a long-term basis at a young age indicate a lack of congruence with international and national guidelines. These findings highlight the need for [...]